Generic Pharmaceuticals Contract Manufacturing Market Size, Share, and Trends 2024 to 2034

Generic Pharmaceuticals Contract Manufacturing Market Size and Top Companies

The global generic pharmaceuticals contract manufacturing market size was USD 72.50 billion in 2023, calculated at USD 76.73 billion in 2024, and is expected to reach around USD 135.36 billion by 2034, expanding at a CAGR of 5.84% from 2024 to 2034. Asia Pacific dominated the generic pharmaceuticals contract manufacturing market with the largest revenue share of 39% in 2023.

The benefits of generic pharmaceuticals contract manufacturing include reduced costs on running the facility, hiring in-house personnel, and manufacturing equipment, reduced time, produces a high number of products, collaboration and knowledge exchange, advanced technologies, etc. help to the growth of the market.

Generic Pharmaceuticals Contract Manufacturing Market Key Takeaways

• North America is estimated to be the fastest-growing during the forecast period of 2024-2033.
• By drug type, the branded generics segment has contributed more than 63% of revenue share in 2023.
• By drug type, the unbranded generics segment is significantly growing during the forecast period.
• By product, the API product segment has held a major revenue share of 58% in 2023.
• By route of administration, the oral segment has captured the largest revenue share of 62% in 2023.
• By route of administration, the parenteral segment is anticipated to be the fastest-growing during the forecast period.
• By application, the oncology segment has generated the biggest revenue share of 23% in 2023.
• By application, the immunology segment is expected to be the fastest-growing during the forecast period.

Asia Pacific Generic Pharmaceuticals Contract Manufacturing Market Size and Growth 2024 to 2034

The Asia Pacific generic pharmaceuticals contract manufacturing market size was exhibited at USD 28.28 billion in 2023 and is projected to be worth around USD 53.47 billion by 2034, poised to grow at a CAGR of 5.96% from 2024 to 2034.

Asia Pacific dominated the generic pharmaceuticals contract manufacturing market in 2023. The rising demand for generic drugs & biologics is due to their cost-efficiency, rising investments in pharmaceuticals R&D, patent expiration, manufacturers’ increasing affection towards the use of cutting-edge technologies, and critical manufacturing requirements of advanced technologies by supporting the industry in the growth of the market in the Asia Pacific region. In India, there is a demand for generic medicines in the drug market. In India, the top generic medicine manufacturers or CMOs include Aurobindo Pharma, Teva Pharmaceutical, Sandoz International, Zydus Cadila Healthcare, Lupin, Cipla, MSN laboratories, Baxter International, Alkem Laboratories, Sun Pharmaceutical, Reddy’s Laboratories Ltd., Protech Telelinks, etc. which help to the growth of the market.

• In February 2024, the Store Generics was launched by MedPlus Health Services, a Hyderabad-based retail pharmacy and diagnostics chain to promote the use of generic drugs.

North America is estimated to be the fastest-growing during the forecast period of 2024-2033. In the U.S. and Canada, increasing pharmaceutical industries helped the growth of the generic pharmaceuticals contract manufacturing market in North America. Teva Pharmaceutical Industries Ltd is the leading company in generic manufacturing in the United States.

• In September 2023, in the U.S. market, a complex oral buccal/sublingual film generic to suboxone was launched by a pharmaceutical company, DifGen Pharmaceuticals LLC.

Market Overview

The generic pharmaceuticals contract manufacturing market involves partnerships between contract manufacturing providers and brand-name pharmaceutical companies to expand the production of generic equivalents and follow-on biosimilars (biologics). The market is a part of the pharmaceutical and biotechnology industries that involves the production and manufacturing of generic pharmaceutical products by pharmaceutical companies to contract manufacturing organizations. This helps pharmaceutical companies to support the expertise and infrastructure of contract manufacturing organizations to produce generic drugs effectively and at low cost. This helps companies to focus on development, research, and marketing. These factors help to the growth of the market.

Generic Pharmaceuticals Contract Manufacturing Market Growth Factors

• The benefits of contract manufacturing organizations for generic pharmaceutical companies include helping to reduce costs.
• It also helps to offer flexibility and capability to meet changing market demands, reduce risks, and take responsibility for the project which helps to the growth of the market.
• Generic pharmaceuticals contract manufacturing organizations can help to improve time to market which helps to shorten the product lead time.
• Generic pharmaceutical contract manufacturing organizations have good manufacturing practices (GMP) compliance and essential expertise and infrastructure to manufacture drugs according to the market regulations, which helps to grow the generic pharmaceuticals contract manufacturing market.

Market Scope

Market Dynamics

Driver

Rising investments in pharmaceutical R&D activities

Rising investment in pharmaceutical R&D activities can help the growth of the market. R&D allows businesses to acquire ever-changing market and consumer needs. R&D may provide a new direction for processes, products, or services, and it can improve productivity and reduce costs, help companies stay ahead or follow market trends, and keep them relevant. These factors help to grow the generic pharmaceuticals contract manufacturing market.

Restraint

Risks of generic pharmaceutical contract manufacturing

The risks of generic pharmaceutical contract manufacturing include ensuring compliance with regulatory standards may be challenging, depending on a single manufacturing organization, may lead to supply chain risks, sharing of proprietary production and formulation processes with contract manufacturing organizations, raises problems related to intellectual property protection, communication hurdles that helps to maintain quality and ensures compliance with regulatory standards is a priority. These factors help to grow the generic pharmaceuticals contract manufacturing market.

Opportunities

Expansion of complex generic drugs

Pharmaceutical and biotechnology industries look at an increase in the production of complex generic drugs, which are more demanding to test, administer, and manufacture than traditional generics. These drugs include products with delivery systems, complex formulations, active ingredients, devices, or dosages, which are made up of complex molecular structures. These drugs are highly critical to regenerate as its generic version. There is an opportunity for the expansion of complex generic drugs. These factors help to grow the generic pharmaceuticals contract manufacturing market.

Telemedicine and tele-pharmacy

As how healthcare is delivered, telemedicine and tele-pharmacy are changing, allowing remote patient consultations and management of medication prescriptions. The COVID-19 pandemic increased acceptance of these technologies; at that time, virtual care technology was necessary, which led to faster development and made it easy to access essential medicines. The increase in telemedicine and tele-pharmacy may enhance patient faithfulness and eliminate medication-related concerns, especially in underserved or rural areas as local pharmacies have been set down, because various patients may not have the economic conditions to pay expensive brand name costs or to travel for healthcare. Telemedicine and tele-pharmacies' mail-in medicine delivery systems help patients get access to affordable generics anywhere they are located. These telemedicine and tele-pharmacy technology opportunities help the growth of the generic pharmaceuticals contract manufacturing market.

Drug Insights

The branded generics segment dominated the market in 2023. Branded generics are not under any patent and are sold using a brand name instead of its chemical name. Branded generics may be developed by the original manufacturer or by a generic drug firm. Branded generics are more costly than unbranded generics. Branded generics are the brand name given to a drug that is bioequivalent to an innovator (original) brand. Once the original brand comes off patent, it is marketed under another company’s brand. These factors help the growth of the branded generics segment and contribute to the growth of the generic pharmaceuticals contract manufacturing market.

The unbranded generics segment is anticipated to grow significantly during the forecast period. An unbranded product is sold under the name of the product itself or the name of the shop, alternately the name of the company that made it. Unbranded generics maybe half the price of big brand names. Unbranded generics have the same active molecule but are sold under the chemical name. The advantages of unbranded generics include that they are more affordable and save money than branded generics, are easily available, safe, and quality, are approved by the drug advisory board, and have insurance coverage.

Companies developing generics do not need to invest high amounts of time and research due to FDA approval and testing of the brand drug’s ingredients already being completed. The unbranded generics may get to market faster and can be sold greatly cheaper than branded generics. These factors help the growth of the unbranded generics and contribute to the growth of the generic pharmaceuticals contract manufacturing market.

Product Insights

The API product segment dominated the market in 2023. The benefits of API products for organizations: developers use APIs to research and develop new services, enhance business models, reliability, and functionality, access data, and complete their product development. The APIs are the active ingredients contained in the medicine.

The API is that part of the medicine that medicines that produce therapeutic effects. An API to relieve pain is used as a painkiller. These factors help the growth of the API product segment and contribute to the growth of the generic pharmaceuticals contract manufacturing market.

Route of Administration Insights

The oral category segment dominated the market in 2023. The oral route of administration is the most preferred drug delivery system. The benefits of the oral category route of administration include less expensive, most convenient, and most convenient. Although, it has limitations due to the way drugs usually move through the digestive tract. The oral route of administration and absorption can begin with the stomach and mouth. The advantages of the oral route of administration are flexibility in dosage forms, high patient compliance, pain-free, cost-effectiveness, and simplicity. The prerequisite for oral drug delivery may be significant aqueous solubility, which leads to improved bioavailability. These factors help the growth of the oral category segment and contribute to the growth of the generic pharmaceuticals contract manufacturing market.

The parenteral segment is estimated to be the fastest-growing during the forecast period. The advantages of the parenteral route of administration include the fact that it can deliver an accurate dose of medication rapidly, it may be directly injected into the tissue or circulatory system, or it bypasses liver metabolism. The benefits of parenteral administration also include the fact that they are more quickly absorbed and have a faster onset of action than the oral route of administration, reliable dosage, better bioavailability, and first-pass metabolism avoidance. Parenteral routes of administration are better for drugs with poor absorption in the GIT (gastrointestinal tract) that are destroyed by digestive secretions or not orally effective. These factors help the growth of the parenteral segment and contribute to the growth of the generic pharmaceuticals contract manufacturing market.

Application Insights

The oncology segment dominated the generic pharmaceuticals contract manufacturing market in 2023. The benefits of generic pharmaceuticals contract manufacturing for oncology include it helps to treat ovarian cancer, blood cancer, lung cancer, testicular cancer, etc. This helps to prevent cancer cell growth. The benefits of cancer treatment include chemotherapy, which can slow down cancer growth or shrink cancer, which can help to live longer and with your symptoms. These factors help the growth of the oncology segment and contribute to the growth of the market.

The immunology segment is estimated to be the fastest-growing during the forecast period. The benefits of generic pharmaceuticals contract manufacturing for immunology drugs include helping to improve immune response by suppressing or enhancing the immune system. These are used to treat and prevent specific diseases and can fight infections. Immunology drugs are used for immunosuppression to prevent immunological response. The immunology drugs treat many conditions, such as autoimmune and cancer diseases. These factors help to the growth of the immunology segment and contribute to the growth of the generic pharmaceuticals contract manufacturing market.

Generic Pharmaceuticals Contract Manufacturing Market Companies

• Metrics Contract Services
• Curia Global, Inc.
• Pfizer Centre One
• Syngene International Ltd.
• Acme Generics Pvt Ltd.
• Catalent, Inc.
• Alcami Corp., Inc.
• Cambrex Corp.
• Aurobindo Pharma
• Siegfried Holding AG
• Recipharm AB
• Jubilant Generics Ltd.
• Metrics Contract Services

Recent Developments

• In July 2023, Breyna Inhalation Aerosol, the first generic version of AstraZeneca’s Symbicort with an ANDA (abbreviated new drug application), was approved by the U.S. FDA (Food & Drug Administration) and launched by a global health company Viatris Inc. and Kindeva Drug Delivery L.P. for people with chronic obstructive pulmonary disease and asthma.
• In November 2023, an antibiotic manufacturing facility in Kundl, Austria was opened by a generic pharmaceuticals company based in Switzerland, Sandoz Group AG. In Europe, to strengthen the future of antibiotics manufacturing Sandoz invested $160.4m.
• In February 2024, in the United States, 5-6 new products in each quarter were planned to be launched by Alembic Pharmaceuticals, a Vadodara-based generics drugmaker.

Segments Covered in the Report

By Drug

• Branded Generics
• Unbranded Generics

By Product

• API
• Drug Product

By Route of Administration

• Oral
• Parenteral
• Topical
• Others

By Application

• Oncology
• Immunology
• Antidiabetic
• Neurology
• Anticoagulants
• Cardiovascular
• Respiratory
• Pain
• HIV antivirals
• Others

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa